Regorafenib — Drug Intelligence | 34 EU Trials

Filter these 34 trials by condition, phase, country and more.

Open in Search →

34 Registered trials

14 Recruiting

19 Completed trials

31 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase III: 9 Phase II/III: 2 Phase II: 17 Phase I/II: 4 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Colorectal cancer metastatic 5 Osteosarcoma metastatic 2 Ewing´s sarcoma metastatic 2 Malignant melanoma stage IV 1 Rectal cancer stage III 1 Chondrosarcoma metastatic 1 Ewing's sarcoma recurrent 1 Malignant melanoma stage III 1 Rectal cancer stage II 1 Osteosarcoma recurrent 1 Colon cancer metastatic 1 Gastrooesophageal cancer 1

Sponsors using this IMP

Bristol Myers Squibb International Corporation 2 Centre Hospitalier Universitaire Rouen 2 Centre Leon Berard 2 Agenus Inc. 1 Amgen Inc. 1 Arcus Biosciences Inc. 1 Bayer AG 1 Bristol-Myers Squibb Services Unlimited Company 1 Centre Hospitalier Universitaire De Nantes 1 Cliniques Universitaires Saint-Luc 1 Exelixis Inc. 1 Fondazione GONO G.I. 1

All trials

34 total

Monocentric Pilot Trial evaluating the safety and efficacy of Regorafenib in Arterio-Venous Malformations that are refractory to standard ca… Pending

2022-501830-47-01 Phase II 1 country Cliniques Universitaires Saint-Luc
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta… Recruiting

2023-503322-39-00 Phase I (Other) 5 countries Institut Gustave Roussy
Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting

2024-519669-23-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Phase I/II 1 country Oncomatryx Biopharma S.A.
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting

2024-516709-22-00 Phase II/III 1 country Centre Hospitalier Regional Universitaire
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
Regorafenib for recurrent meningioma. A multicenter, randomized phase II study (MIRAGE trial) Recruiting

2024-510954-28-01 Phase II 1 country Istituto Oncologico Veneto
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Phase III 1 country Centre Hospitalier Regional Universitaire
A phase-2 clinical trial of regorafenib in patients with pretreated advanced melanoma Recruiting

2024-514087-11-02 Phase II 1 country UZ Brussel
Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA… Recruiting

2024-518534-81-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Phase I/II 16 countries The University Of Birmingham
Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of pa… Recruiting

2023-510567-35-00 Phase II 1 country Centre Leon Berard
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
Study describing the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone sarcomas Recruiting

2024-514637-37-00 Phase III 1 country Centre Leon Berard
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A study of continued treatment with regorafenib in participants with solid tumors who have participated in other Bayer studies Ended

2023-507084-19-00 Phase II 2 countries Bayer AG
Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga… Ended

2022-502065-23-00 Phase II 4 countries Agenus Inc.
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Phase III 7 countries Exelixis Inc.
To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors. Ended

2024-514720-17-00 Phase II 1 country Instytut Matki I Dziecka
Adjuvant therapy in stage IV colorectal cancer patients NED Ended

2024-518217-26-00 Phase II 1 country IRCCS Ospedale Policlinico San Martino
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Phase II 1 country Institut Jules Bordet
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Phase II 1 country Fondazione GONO G.I.
Trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failur… Ended

2024-512555-21-00 Phase III 1 country Institut Regional Du Cancer De Montpellier
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors Ended

2023-509500-15-00 Phase I/II 1 country Institut Bergonie

Showing 1–24 of 34 trials

← All drugs A–Z